Osteoporosis Management

Indications for Pharmacological Therapy

Pharmacological therapy is not indicated when the T-score is > -1.5 without additional risk factors, according to the American Society of Clinical Oncology 1
Pharmacological treatment should be considered in patients with a T-score ≤ -1.5 or additional risk factors, such as age >65 years with additional risk factors, as recommended by the American Society of Clinical Oncology 1
Patients with two or more risk factors, including age >65, smoking, BMI <24, and family history of hip fracture, should be considered for pharmacological treatment, as suggested by the American Society of Clinical Oncology 1
Denosumab (RANK-L inhibitor) may be considered in certain patients as an alternative option, according to the American Society of Clinical Oncology 1
Treatment for osteopenia should be considered in patients with a T-score less than -1.5 with additional risk factors, as recommended by the Journal of Crohn's and Colitis 2
The American College of Rheumatology recommends pharmacologic treatment for osteoporosis when the T-score is ≤ -2.5, or when there is a history of fragility fracture, or when the FRAX score indicates a high risk of fracture 3, 4

The T-score is the standard metric used for diagnosing osteoporosis in postmenopausal women and men aged 50 years or older, representing the number of standard deviations a person's BMD differs from the young, healthy norm, with a T-score of -2 indicating a BMD that is 2 SDs below the comparative norm 5
The international reference standard for diagnosing osteoporosis is a femoral neck BMD of 2.5 SD or more below the young female adult mean 5
The following categories are used to classify bone density:
Category T-score
Normal BMD ≥ -1.0
Osteopenia/low bone mass -1.0 to -2.5
Osteoporosis ≤ -2.5
6, 7, 8, 9
A Z-score ≤ -2.0 indicates "Low BMD for chronological age" or "below the expected range for age" 5
The World Health Organization (WHO) classifies bone mineral density (BMD) using T-scores, with normal BMD defined as a T-score ≥ -1.0, osteopenia/low bone mass as a T-score between -1.0 and -2.5, and osteoporosis as a T-score ≤ -2.5, as established by the WHO criteria and clinical guidelines 8, 6, 7, 9

First-line treatment typically includes oral bisphosphonate therapy (alendronate, risedronate) and adequate calcium and vitamin D supplementation (1,000-1,200 mg daily and 600-800 IU daily, respectively), with a high level of evidence 5, 10
Lifestyle modifications, including weight-bearing exercise (30-40 minutes, 3-4 times weekly), smoking cessation, limiting alcohol consumption to ≤2 drinks/day, and fall prevention strategies, are essential for patients with osteopenia, with a high level of evidence 2, 11, 5, 10
Calcium supplementation (1000-1200 mg/day) if dietary intake is inadequate (<800 mg/day) and vitamin D supplementation (800-1000 IU/day) to maintain recommended serum levels are recommended for patients with osteopenia, as suggested by the American Academy of Family Physicians 2, 11

If starting pharmacological therapy, compliance should be assessed at follow-up visits, as recommended by the American Society of Clinical Oncology 1
BMD testing alone is an imperfect predictor of fracture risk, identifying less than half of people who will develop osteoporotic fractures 5
Risk assessment tools like FRAX (WHO Fracture Risk Assessment Tool) incorporate clinical risk factors with or without BMD to compute fracture probability, highlighting the importance of considering multiple factors beyond BMD 8
Follow-up BMD testing is recommended every 1-2 years to assess bone loss progression, using the same DEXA machine for serial measurements, as suggested by the International Osteoporosis Foundation 1
Clinical assessment should be performed every 6 months, and follow-up BMD testing should be done every 12 months to assess treatment efficacy, with a moderate level of evidence 11
Serial BMD monitoring should be performed on the same equipment using the same reference standards, and changes in BMD should be assessed using absolute BMD values (g/cm²), not T-scores or Z-scores, with a high level of evidence 8

Misinterpreting terminology by using "osteoporosis" as a synonym for "low bone mass" is incorrect and may lead to overtreatment, with a low level of evidence 12
Overlooking age context, as a T-score of -2.0 (osteopenia) in a young individual may indicate worse long-term bone health than a T-score of -2.6 (osteoporosis) in an older individual, with a moderate level of evidence 12
Relying solely on BMD, as fracture risk depends on multiple factors beyond BMD, including age, previous fractures, and other clinical risk factors, with a high level of evidence 13
Ignoring treatment thresholds, as not all patients with low bone mass require pharmacologic treatment, while all patients with osteoporosis generally do, with a moderate level of evidence 6, 13